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1. Introduction
  Multidrug resistant bacteria causing therapeutic problems 
have become a matter of serious concern in both in hospital 
and community settings[1]. Extended spectrum 毬-lactamases
(ESBLs) are the bacterial enzymes that impart resistance 
against advanced-generation cephalosporins. There is 
a widespread occurrence of ESBLs, particularly in the 
hospital environment[2,3]. ESBLs are dangerous because they 
are plasmid-associated and there can be cross-species 
dissemination of these plasmids. Moreover, these plasmids 
can carry genes for co-resistance to other antibiotics 
such as aminoglycosides, fluoroquinolones, tetracyclines, 
chloramphenicol and sulfamethoxazole-trimethoprim. 
Antibiotic selection for such isolates thus becomes a 
therapeutic challenge. The widespread clinical use of 
broad spectrum 毬-lactam antibiotics has led to a marked 
increase in the incidence of ESBL-producing gram-negative 
microbes[4,5].
  The majority of ESBLs are derived from the widespread 
broad-spectrum 毬-lactamases TEM-1 and SHV-1[6,7]. 
However, the prevalence of occurrence of these organisms 
varies significantly in different geographical regions. CTX-
Ms are a class of ESBLs that are named after the antibiotic 
‘cefotaxime’. CTX-Ms have become the most prevalent 
ESBLs worldwide[8] but have most often been associated 
with focal outbreaks in Eastern Europe, South America, 
Southeast Asia-Japan and recently in India with many 
variants described[9,10]. CTX-M type ESBLs are mainly found 
in Escherichia coli (E. coli) strains and CTX-M producers 
are extremely common in UTIs[11]. The CTX-M-15 enzyme 
in particular is increasingly being reported among E. coli 
isolates from northern india. In view of this background 
we have initiated this study to characterize the bacterial 
pathogens in patients having gram negative septicaemia. 
Further, to evaluate the antimicrobial resistance and 
underlying molecular mechanisms in these strains. The 
Objective: To characterize the bacterial pathogens in patients having gram negative septicaemia. 
Further, to evaluate the antimicrobial resistance and underlying molecular mechanisms in these 
strains. Methods: A total number of 70 cases of gram negative sepsis were included in this 
prospective, open labeled, observational study. Standard methods for isolation and identification 
of bacteria were used. Antimicrobial susceptibility and ESBL testing was performed by the 
standard disc diffusion method. PCR amplification was performed to identify  blaCTX-M, blaSHV and 
blaTEM type ESBLs. Conjugation experiments were performed to show resistant marker transfer. 
Results: The most prevalent isolates Escherichia coli (E. coli) 58.6%, Klebsiella Spp. 32.9% and 
Pseudomonas 8.6%, were resistant to most of the antimicrobials including cefazolin, ceftriaxone, 
cefuroxime, ampicillin and co-trimoxazole but sensitive to imipenem and meropenem. ESBL 
and MBL production was seen 7.3% and 12.2% of E. coli isolates respectively. Three isoaltes 
were found to have blaCTX-M-15 and two of them also showed blaTEM-1 type enxyme. Whereas, 
none of them showed blaSHV. Conjugation experiments using J-53 cells confirmed these resistant 
markers as plasmid mediated. Conclusions: This work highlights the molecular epidemiology of 
escalating antimicrobial resistance and likely switch over of blaCTX-M-15 type extended spectrum 
beta-lactamases by blaTEM type ESBLs in India. Further, the antimicrobial resistance by horizontal 
gene transfer was predominant among Enterobacteraceae in the community setting.
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present study was undertaken; to assess the prevalence 
of plasmid mediated ESBL in Medical ICU of a teaching 
hospital in North India.
2. Material and methods
  The present study was conducted in the Department of 
Medicine, and Interdisciplinary Biotechnology Unit of AMU, 
India.
2.1. Inclusion criteria
  Patients having clinical features and bacteriological 
evidence of sepsis, septic shock, multi organ dysfunction 
and/or systemic manifestations of gram negative septicaemia.
2.2. Exclusion criteria
  Immunocompromised, patients with disseminated TB, 
HIV and patients on steroids were excluded from the study. 
Informed written consent was given by all study subjects and 
the study was approved by Institutional Ethics committee.
2.3. Study design
  Prospective, observational, non-interventional studies of a 
two tertiary care teaching hospital.
2.4. Isolation and identification of organism
  On admission appropriate culture: urine, sputum, pus, 
urinary catheter tip, tracheal aspirate was sent in vials using 
standard techniques. Standard methods for isolation and 
identification of bacteria were used throughout the study[12]. 
The identified bacteria were also confirmed by the selective 
media of the ‘Hi-crome series’ (Hi-media, Mumbai, India).
2.5. Antimicrobial susceptibility and ESBL detection
  Antimicrobial susceptibility and ESBL testing was 
performed was performed by the standard disc diffusion 
method as recommended by the Clinical and Laboratory 
Standards Institute[13]. E. coli ATCC 25922 was used as ESBL 
negative and K. pneumoniae 700603 was used as ESBL-
positive reference strain. 
2.6. DNA preparation and PCR amplification
  Plasmid DNA was prepared by using methods of Birnboim 
and Doly[14], and genomic DNA by the method of Boom 
et al[15]. PCR amplification of ESBLs markers gene were 
performed on 0.5 mg of genomic DNA as described earlier[16]. 
Primers for the detection of blaCTXM (5’-GCT GTT GTT AGG 
AAG TGT GC-3’ and 5’-CCA TTG CCC GAG GTG AAG-3’), 
blaTEM (5’-GAC AGT TAC CAA TGC TTA ATC-3’ and 5’-
GAC AGT TAC CAA TGC TTA ATC-3’) and blaSHV(5’-TGG 
TTA TGG GTT ATA TTC GCC-3’ and  5’-GGT TAG CGT TGC 
CAG TGCT-3’) were used. PCR conditions for these genes 
comprised a thermal temperature to 94 曟 for 5 min, followed 
by 35 cycles of 94 曟 for 30 s, annealing at 54 曟 for 30 s, 
and extension at 72 曟 for 1 min, followed by final extension 
for 7 min at 72 曟.
2.7. Marker transfer experiments
  Marker transfer experiments were performed to check the 
transmissibility of the blaCTX-M resistance markers and to ask 
for co-transferred markers. E. coli strains that were PCR-
positive for any of the tested genes were used as donors in 
transconjugation experiments as described elsewhere[17]. 
Azide-resistant E. coli J53 was used as the recipient in all 
marker transfer experiments. Transconjugants/transformants 
were selected on Luria-Bertani agar plates containing azide 
(250 mg/L) and either cefotaxime (2 mg/L) or gentamicin
(50 mg/L).
3. Results
3.1. Clinical background of isolates
  Total 70 patients with mean age of (55.94依10.77) years, 
predominantly men (70%) and women (30%) were studied. 
On clinical evaluation, urinary tract (61.4%) was the most 
common site of infection, followed by respiratory tract 
(28.6%) and skin and soft tissue (10.0%). The most common 
organism encountered for sepsis was E. coli 41(58.6%) 
followed by Klebsiella Spp. 23(32.9%) and Pseudomonas 
6(8.6%). In patients having urosepsis most common 
organism responsible was E. coli 35(81.4%) followed by 
Klebsiella Spp. 6(14.0%) and Pseudomonas 2(4.6%). In 
patients having pneumonia with sepsis the most common 
organism encountered was Klebsiella Spp. 15(75.0%) 
followed by Pseudomonas 4(20.0%) and E. coli 1(5.0%). In 
patients having diabetic foot with sepsis in the study group 
most common organism encountered was E. coli 5(71.0%) 
followed by Klebsiella Spp. 2(28.6%). The most common 
co-morbidity was diabetes mellitus 35(50.0%), followed 
by benign prostatic hypertrophy 10(14.3%) and chronic 
obstructive airway disease 3(4.3%) (Table 1).
3.2. Antimicrobial resistance
  In the study group, E. coli, Klebsiella  Spp. and 
Pseudomonas found to be resistant to gatifloxacin in 31.7%, 
17.4% and 66.7% patients respectively. E. coli, Klebsiella 
Spp. and Pseudomonas were found to be resistant to the 
amikacin in 43.9%, 69.6% and 16.7% patients respectively. 
E. coli showed 7.3% intermediate resistance to Amikacin. 
All the three organisms were 100.0% resistant to ampicillin 
and co-trimoxazole. E. coli and Pseudomonas showed 
0% resistance to Imipenem on the other hand Klebsiella 
Spp. showed 4.3% resistance. E. coli, Klebsiella Spp. and 
Pseudomonas were found to be resistant to meropenem 
in 9.7%, 17.4% and 50.0% patients respectively. E. coli 
and Klebsiella Spp. showed intermediate resistance to 
meropenem in 4.8% and 47.8% patients respectively. Most 
of the gram negative organisms are sensitive to imipenem 
and meropenem. Almost all gram negative organisms (E. coli,
Klebsiella Spp. and Pseudomonas) were resistant to co-
trimoxazole (Table 2).
3.3. Molecular analysis of ESBLs
  In the present study 7.3% E. coli isolates showed ESBL 
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production while 12.2% showed MBL production on the other 
hand Klebsiella Spp. and Pseudomonas showed no ESBL/
MBL production. In the present study majority of the isolates 
encountered for gram negative sepsis was E. coli (58.6%), 
and 81.4% E. coli were isolated from patients having 
urosepsis. In the present study only 3 (7.3%) E. coli strains 
had a phenotype consistent with production of an ESBL. 
These 3 E. coli isolates were screened for the presence of 
ceftrixone hydrolyzing 毬-lactamases (CTX-M) and blaTEM 
and blaSHV types by PCR using universal primers. Three 
isolates (UE-59, UE-61, and UE-64) showed the presence 
of blaTEM, and blaCTX-M type enzyme, while all the three 
were found negative for SHV (Figure 1 & 2). Furthermore, 
conjugation experimenst using J-53 as recipient susceptible 
cells confirmed that these markers are present on plasmid.




Figure 1. PCR amplification of CTX-M gene.
Lane M: DNA ladder; Lane P: Positive control; Lane 1-3: E. coli 
clinical isolates (UE-59, UE-61, and UE-64); Lane N: Negative 
control.





Figure 2. PCR amplification of TEM gene.
Lane M: DNA ladder; Lane P: Positive control; Lane 1-3: E. coli 
clinical isolates (UE-59, and UE-64); Lane N: Negative control.
4. Discussion
  Gram-negative sepsis is a significant problem in 
hospitalized and community-dwelling patients. Although 
the percentage of hospital-acquired bloodstream infections 
associated with gram-negative bacilli has decreased, these 
organisms now pose serious therapeutic problems because 
of multidrug resistance[18].
  The treatment of gram-negative bacteremia is increasingly 
complicated by the occurrence of multidrug resistant gram-
Table 1
Percent etiology and sources of sepsis(n,%).
Source of sepsis E. coli Klebsiella Spp Pseudomonas Total
Urosepsis 35(85.36)   6(26.08) 2(33.33) 43(61.40)
Pneumonia   1(2.49) 15(65.21) 4(66.66) 20(28.60)
Diabetic foot   5(12.19)   2(8.69)   0(0.00)   7(10.00)
Table 2
Percentage of resistance to the selected antimicrobial agents among the Gram negative bacteria.
Pathogens
(ESBL- producing) 
毬-Lactam Aminoglycosides Flouroquinolne Cycline Cloxacillin Cephalosporin groups Carbapenem
A P G Tb Ak Na Cip Gat Te Cot Cox Cz Cn Ce Ci Cpm Mrp Etp Ipm
E. coli (41 isolates) 100.0 100.0 43.9  51.0 43.9 100.0 100.0 31.7 95.1 100.0 100.0 100.0 100.0 100.0 100.0 100.0  9.7  0.0 0.0
Klebsiella((23 isolates) 100.0 100.0 28.0 100.0 69.6 100.0 100.0 17.4 87.0 100.0   10.0  91.3   91.3  91.4  95.6  95.6 17.4  4.3 4.3
Pseudomonas(6 isolates) 100.0   16.0 12.0   12.0 16.7 100.0 100.0 66.7 83.3 100.0   58.0 100.0 100.0 100.0 83.3 100.0 50.0 33.0 0.0
A=Ampicillin, P=Penicillin, G=Gentamicin, Tb=Tobramycin,  Ak=Amikacin, Na=Nalidixic acid, Cip=Ciprofloxacin, Gat=Gatifloxacin, 
Te=Tetracycline, Cot=Cotrimoxazole, Cox=Cloxacillin, Cz=Cefazolin, Cn=Cephoxitin, Ce=Cephotaxime, Ci=Ceftriaxone,  Cpm=Cefepime, 
Mrp=Meropenem, Etp=Ertapenem, Ipm=Imipenem.
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negative bacilli strains. Over-production of chromosomal 
beta-lactamases by Enterobacter Spp. has become one of the 
most common mechanisms of resistance to third generation 
cephalosporins[19]. 
  In our study group most common organism encountered 
for sepsis was E. coli 41(58.6%) followed by Klebsiella  Spp. 
23(32.9%) and Pseudomonas 6(8.6%). Similar results for the 
most common isolates were identified in community acquired 
sepsis in an Italian study:  E. coli (76.0%); P. aeruginosa(7.9%);
K. pneumoniae (5.4%); Proteus mirabilis-4.2 percent; 
Enterobacter species-3.7 percent[20]. UTI remains the 
commonest type of community acquired gram negative 
sepsis, especially in developing countries.
  Similar type of study done by Geoffrey D. Taylor et al  in 
nosocomial urosepsis showed  most common organism 
responsible was E. coli (36.8%)  and 8.9% Pseudomonas[21]. 
In our study most common organism isolated from patients 
having pneumonia was Klebsiella Spp. 15(75%) followed 
by Pseudomonas 4(20%) and E. coli 1(5%). A similar study 
done by C. Feldman et al who found 31.9% isolates were 
Klebsiella Spp and 8.9% were Pseudomonas[22].
  In our study E. coli, Klebsiella Spp. and Pseudomonas were 
found to be resistant to cefazolin & cefuroxime in 100.0%, 
95.6% and 100.0% respectively. For ceftazidime, E. coli was 
found to be 100.0% resistsnt, Klebsiella Spp. showed 91.4% 
resistance and Pseudomonas showed 83.3% resistance. Our 
findings are comparable to study conducted by Kumari et 
al[23].
  In the present study 7.3% E. coli isolates showed 
ESBL production on the other hand Klebsiella Spp. and 
Pseudomonas showed no ESBL/metallo-betalactamase 
(MBL) production.While MBL production was seen in 
12.2% E. coli. ESBL and MBL production is a matter of 
great concern in the field of microbial drug resistance.
ESBLs represent a major threat among resistant bacterial 
isolates of Enterobacteriacea[24]. This renders powerful 
antibiotics, like expanded spectrum cephalosporins, 
carbapenems, and monobactams, ineffective. India has 
significantly high pool of ESBL infections, reflecting poor 
standards of hygiene and inappropriate use of antibiotics, 
as compared to other developed societies. The source of 
ESBL producing Enterobacteriacea differ, while in other 
countries it is mainly hospital acquired, in India it is mostly 
community acquired[25]. Different groups of ESBLs, have 
been described and classified according to their amino-
acid sequences, like SHV-1, TEM-2, TEM-3 etc. Until 
the end of the 1990s, most of the ESBLs detected were 
SHV and TEM types, mostly associated with nosocomial 
outbreaks[26]. In 1989, almost simultaneously in Germany, 
France and Italy, a new ESBL family was recognised. It 
was named CTX-M, because most of the enzymes within 
this family confer resistance predominantly to cefotaxime 
rather than ceftazidime[27]. The CTX-M ESBLs have since 
been detected in many species of Enterobacteriaceae. 
Currently the CTX-M family includes more than 20 beta-
lactamases, which may be grouped on the basis of sequence 
similarity into 4 distinct subtypes epitomized by CTX-
M-1, CTX-M-2, CTX-M-8 and CTX-M-9. The blaCTX-M-
15 gene borne on plasmid in Enterobacteriaceae, was first 
detected in India, which is now the globally dominant 
ESBL[28]. Unlike in other countries e.g. Spain, France, 
where members of multiple CTX-M lineages have been 
reported, a virtually absolute prevalence of the members 
of the CTX-M-1 lineage was observed in this study[26].
  Recent reports have shown a rapid and alarming 
dissemination of Enterobacteriaceae producing ESBLs of the 
CTX-M type in certain countries including India and have 
become the most  prevalent ESBL-type world-wide[29]. The 
majority of these isolates are now recovered from community 
patients, most of them with urinary tract infections[30].Unlike 
that of TEM or SHV type ESBLs, the population structure of 
CTX-M-producing isolates is complex and is associated 
with the spread of specific plasmids and/or other mobile 
gene -tic elements rather than clonal epidemics[31]. CTX-Ms 
are one of the means of antibiotic resistant marker transfer 
among members of Enterobacteriaceae. However, their 
prevalence in different areas appeared to be highly variable, 
which could reflect the scenario of a relatively early stage 
of dissemination of these resistance determinants in the 
community setting. In the recent past, there are alarming 
reports about the emergence and spread of resistant strains 
of Enterobacteriaceae from all around the world.
  Bacterial resistance to commonly used antibiotics, in a 
resource crunched developing country like India, threatens 
the basic health delivery systems, affecting millions. 
There are alarming reports about serious consequences of 
antibiotic resistance. However, there is still a scarcity of 
data on the magnitude of antibiotic resistance, especially in 
Asia-Pacific region.
  To conclude, this work has provided insights into molecular 
epidemiology of escalating antimicrobial resistance, 
especially prevalent in ESBL producing Enterobacteraceae 
in India. Continuing surveillance will be necessary to 
monitor the evolution of extended spectrum beta-lactamases 
and to authenticate whether the CTX-M type ESBLs will 
eventually prevail over the blaTEM-type ESBLs, which are 
still widespread, especially in some areas. Our findings 
uphold the increasing role of the blaCTX-M 毬-lactamases 
in antibiotic resistance and stress upon the significance of 
appropriate empirical treatment for infections caused by 
coliforms, especially during septicemia. This study confirms 
that horizontal gene transfer of antimicrobial resistance 
markers, is the most prevalent among Enterobacteraceae in 
the community setting. Further studies are needed, however, 
to determine whether antibiotic policies or other measures 
can halt or lower the level of horizontal gene transfer that 
occurs in a hospital or community setting. 
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